Cargando…

Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma

Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three s...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Satoru, Endo, Masashi, Fukuda, Yukiko, Ogawa, Kazunari, Nakamura, Michiko, Okada, Kohei, Kawahara, Masahiro, Akahane, Keiko, Nagatomo, Takafumi, Onaga, Ryutaro, Nishino, Hiroshi, Mori, Harushi, Shirai, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459593/
https://www.ncbi.nlm.nih.gov/pubmed/36157698
http://dx.doi.org/10.1159/000526077
_version_ 1784786548167802880
author Takahashi, Satoru
Endo, Masashi
Fukuda, Yukiko
Ogawa, Kazunari
Nakamura, Michiko
Okada, Kohei
Kawahara, Masahiro
Akahane, Keiko
Nagatomo, Takafumi
Onaga, Ryutaro
Nishino, Hiroshi
Mori, Harushi
Shirai, Katsuyuki
author_facet Takahashi, Satoru
Endo, Masashi
Fukuda, Yukiko
Ogawa, Kazunari
Nakamura, Michiko
Okada, Kohei
Kawahara, Masahiro
Akahane, Keiko
Nagatomo, Takafumi
Onaga, Ryutaro
Nishino, Hiroshi
Mori, Harushi
Shirai, Katsuyuki
author_sort Takahashi, Satoru
collection PubMed
description Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three systems: vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor inhibitions. It was initially developed as an anticancer drug for non-small-cell lung carcinoma; however, it was also found to inhibit the proliferation of fibroblasts associated with chronic inflammation in the lungs. Therefore, it is being more widely used to treat idiopathic pulmonary fibrosis, a benign disease, than as an antineoplastic agent. Several studies have reported adverse events associated with the concurrent use of MKIs with surgery or radiotherapy. Specifically, there has been a report cautioning against delayed wound healing associated with the use of nintedanib in patients undergoing surgery. However, there is no specific mention of its concurrent use during irradiation. We describe a case of a 72-year-old man with severely delayed recovery from radiation mucositis when nintedanib was being administered for benign disease.
format Online
Article
Text
id pubmed-9459593
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-94595932022-09-23 Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma Takahashi, Satoru Endo, Masashi Fukuda, Yukiko Ogawa, Kazunari Nakamura, Michiko Okada, Kohei Kawahara, Masahiro Akahane, Keiko Nagatomo, Takafumi Onaga, Ryutaro Nishino, Hiroshi Mori, Harushi Shirai, Katsuyuki Case Rep Oncol Case Report Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three systems: vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor inhibitions. It was initially developed as an anticancer drug for non-small-cell lung carcinoma; however, it was also found to inhibit the proliferation of fibroblasts associated with chronic inflammation in the lungs. Therefore, it is being more widely used to treat idiopathic pulmonary fibrosis, a benign disease, than as an antineoplastic agent. Several studies have reported adverse events associated with the concurrent use of MKIs with surgery or radiotherapy. Specifically, there has been a report cautioning against delayed wound healing associated with the use of nintedanib in patients undergoing surgery. However, there is no specific mention of its concurrent use during irradiation. We describe a case of a 72-year-old man with severely delayed recovery from radiation mucositis when nintedanib was being administered for benign disease. S. Karger AG 2022-08-30 /pmc/articles/PMC9459593/ /pubmed/36157698 http://dx.doi.org/10.1159/000526077 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Takahashi, Satoru
Endo, Masashi
Fukuda, Yukiko
Ogawa, Kazunari
Nakamura, Michiko
Okada, Kohei
Kawahara, Masahiro
Akahane, Keiko
Nagatomo, Takafumi
Onaga, Ryutaro
Nishino, Hiroshi
Mori, Harushi
Shirai, Katsuyuki
Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title_full Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title_fullStr Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title_full_unstemmed Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title_short Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
title_sort nintedanib-induced delayed mucosal healing after adjuvant radiation in a case of oropharyngeal carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459593/
https://www.ncbi.nlm.nih.gov/pubmed/36157698
http://dx.doi.org/10.1159/000526077
work_keys_str_mv AT takahashisatoru nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT endomasashi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT fukudayukiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT ogawakazunari nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT nakamuramichiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT okadakohei nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT kawaharamasahiro nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT akahanekeiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT nagatomotakafumi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT onagaryutaro nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT nishinohiroshi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT moriharushi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma
AT shiraikatsuyuki nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma